Jerill Thorpe

1.3k total citations
23 papers, 740 citations indexed

About

Jerill Thorpe is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Jerill Thorpe has authored 23 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Immunology and 7 papers in Genetics. Recurrent topics in Jerill Thorpe's work include CAR-T cell therapy research (14 papers), T-cell and B-cell Immunology (9 papers) and Immune Cell Function and Interaction (8 papers). Jerill Thorpe is often cited by papers focused on CAR-T cell therapy research (14 papers), T-cell and B-cell Immunology (9 papers) and Immune Cell Function and Interaction (8 papers). Jerill Thorpe collaborates with scholars based in United States, Germany and France. Jerill Thorpe's co-authors include S. Alice Long, Kristina M. Harris, Kevan C. Herold, Melvin P. Weinstein, Gerald T. Nepom, David C. Tanner, Mario R. Ehlers, Kim L. Joho, L. Barth Reller and Peter S. Linsley and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jerill Thorpe

23 papers receiving 727 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jerill Thorpe United States	12	267	244	227	164	148	23	740
André van Maurik United Kingdom	16	128 0.5×	588 2.4×	85 0.4×	71 0.4×	197 1.3×	35	927
Jane Burgess Australia	14	210 0.8×	162 0.7×	239 1.1×	344 2.1×	98 0.7×	21	670
M. J. Giphart Netherlands	18	254 1.0×	616 2.5×	53 0.2×	165 1.0×	127 0.9×	45	937
T Shibuya Japan	12	129 0.5×	183 0.8×	89 0.4×	82 0.5×	70 0.5×	30	568
S Than United States	11	83 0.3×	488 2.0×	67 0.3×	159 1.0×	57 0.4×	15	845
D Barge United Kingdom	18	146 0.5×	510 2.1×	69 0.3×	171 1.0×	47 0.3×	28	822
Ruby Quartey‐Papafio United Kingdom	13	173 0.6×	457 1.9×	30 0.1×	164 1.0×	53 0.4×	23	692
Jason M. Bannock United States	11	137 0.5×	586 2.4×	55 0.2×	55 0.3×	51 0.3×	11	772
Beena Gulwani-Akolkar United States	16	267 1.0×	695 2.8×	107 0.5×	200 1.2×	85 0.6×	28	947
Eleanor M. Scott United Kingdom	11	547 2.0×	160 0.7×	493 2.2×	191 1.2×	126 0.9×	12	946

Countries citing papers authored by Jerill Thorpe

Since Specialization

Citations

This map shows the geographic impact of Jerill Thorpe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerill Thorpe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerill Thorpe more than expected).

Fields of papers citing papers by Jerill Thorpe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerill Thorpe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerill Thorpe. The network helps show where Jerill Thorpe may publish in the future.

Co-authorship network of co-authors of Jerill Thorpe

This figure shows the co-authorship network connecting the top 25 collaborators of Jerill Thorpe. A scholar is included among the top collaborators of Jerill Thorpe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerill Thorpe. Jerill Thorpe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schett, Georg, Tatyana Feldman, Jeremy S. Abramson, et al.. (2024). P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases. SHILAP Revista de lepidopterología. A115–A116. 2 indexed citations

Olson, N. Eric, Seamus P. Ragan, David J. Reiss, et al.. (2023). Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular Cancer Therapeutics. 22(3). 406–418. 8 indexed citations

Costa, Luciano J., Shaji Kumar, Shebli Atrash, et al.. (2022). Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 140(Supplement 1). 1360–1362. 35 indexed citations

Siddiqi, Tanya, Jacob D. Soumerai, Kathleen Dorritie, et al.. (2021). Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 139(12). 1794–1806. 84 indexed citations

Thorpe, Jerill, Yue Jiang, Julie Rytlewski, et al.. (2021). Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 138(Supplement 1). 3834–3834. 1 indexed citations

Wierda, William G., Kathleen Dorritie, Deborah M. Stephens, et al.. (2021). TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL. Hematological Oncology. 39(S2). 5 indexed citations

Sehgal, Alison R., Gerhard Hildebrandt, Nilanjan Ghosh, et al.. (2020). Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.. Journal of Clinical Oncology. 38(15_suppl). 8040–8040. 5 indexed citations

Siddiqi, Tanya, Kathleen Dorritie, Jacob D. Soumerai, et al.. (2019). TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).. Journal of Clinical Oncology. 37(15_suppl). 7501–7501. 10 indexed citations

Siddiqi, Tanya, Kathleen Dorritie, Jacob D. Soumerai, et al.. (2019). TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. Hematological Oncology. 37(S2). 109–110. 1 indexed citations

10.

Anderson, Warren, Jerill Thorpe, S. Alice Long, & David J. Rawlings. (2019). Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells. The Journal of Immunology. 203(12). 3166–3178. 17 indexed citations

11.

Lord, James D., S. Alice Long, Donna Shows, et al.. (2018). Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clinical Immunology. 193. 24–32. 21 indexed citations

12.

Siddiqi, Tanya, Jacob D. Soumerai, William G. Wierda, et al.. (2018). Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood. 132(Supplement 1). 300–300. 19 indexed citations

13.

Long, S. Alice, Jerill Thorpe, Kevan C. Herold, et al.. (2017). Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cellular Immunology. 319. 3–9. 62 indexed citations

14.

Thorpe, Jerill, Sara A. Murray, Marc A. Gavin, et al.. (2017). Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. Clinical Immunology. 181. 67–74. 8 indexed citations

15.

Long, S. Alice, Jerill Thorpe, Hannah A. DeBerg, et al.. (2016). Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science Immunology. 1(5). 177 indexed citations

16.

Durinovic‐Belló, Ivana, Vivian H. Gersuk, Chester Ni, et al.. (2014). Avidity-Dependent Programming of Autoreactive T Cells in T1D. PLoS ONE. 9(5). e98074–e98074. 7 indexed citations

17.

McNeil, Lisa K., Leah Price, Cedrik M. Britten, et al.. (2013). A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry Part A. 83A(8). 728–738. 42 indexed citations

18.

James, Eddie A., Roberto Mallone, Nanette C. Schloot, et al.. (2011). Immunology of Diabetes Society T‐Cell Workshop: HLA class II tetramer‐directed epitope validation initiative. Diabetes/Metabolism Research and Reviews. 27(8). 727–736. 20 indexed citations

19.

Mallone, Roberto, Eddie A. James, Lisa Fitzgerald-Miller, et al.. (2011). Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative. Diabetes/Metabolism Research and Reviews. 27(8). 720–726. 18 indexed citations

20.

Tanner, David C., et al.. (1994). Comparison of commercial kits for detection of cryptococcal antigen. Journal of Clinical Microbiology. 32(7). 1680–1684. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact